Martingale Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Martingale Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,849	Closed	-$306K	–	897
2023 Q1	$306K	Buy	+2,849	New	+$328K	0.01%	710

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Martingale Asset Management's RXDX Position: Q2 2023 in Review

Martingale Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,849 shares — an estimated $306K sold.

Martingale Asset Management first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $306K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Martingale Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Martingale Asset Management sold 2,849 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $306K.
Martingale Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Martingale Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $306K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Martingale Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.